Crossmark

Daily single-strength vs. thrice-weekly double-strength trimethoprim/sulfamethoxazole for Pneumocystis jirovecii prophylaxis in kidney transplant recipients: a non-inferiority randomized control trial

Crossref DOI link: https://doi.org/10.1186/s12879-025-11821-6

Published Online: 2025-10-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chantapoh, Wittawin

Kantachuvesiri, Surasak

Sutharattanapong, Napun

Bruminhent, Jackrapong https://orcid.org/0000-0003-0930-8936
Funding

Funding for this research was provided by:

Mahidol University
License Information

Text and Data Mining valid from 2025-10-21

Version of Record valid from 2025-10-21
More Information

Article History

Received: 2 July 2025

Accepted: 25 September 2025

First Online: 21 October 2025

Declarations

:

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below